Shows
Behind BiotechSeason 2| China: Hong Tang on Traditional Chinese Medicine and Targeted Cancer Supportive TherapyHong Tang Biography
Dr. Hong Tang is Chief Medical Officer, and co-founder of OnQuality Pharmaceuticals. Hong is a Board-certified internal medicine physician with more than 15 years’ experience in both drug development and medical affairs, and conducted all phases of clinical trials. She served as VP, Executive Medical Director, Medical Director, and Medical Officer in Dendreon, Juno, Astellas, BMS and NIH. OnQuality Pharmaceuticals is designing targeted cancer supportive care treatments aimed at preventing and treating the intolerable side effects caused by specific cancer drugs. Their mission is to make fighting cancer easier by alleviating the side effects of an...2022-08-0332 min
Behind BiotechSeason 2 | China: George Chen on Building a "In China, for Global" BiotechGeorge Chen Biography
George Chen, MD MBA, is an oncologist by training with a successful track record in the world of global pharmaceutical companies. Prior to founding D3 Bio, Dr. Chen held senior global positions in research, drug development and management at leading institutions, such as the National Institutes of Health, and multinational pharmaceutical companies, such as Eli Lilly, GlaxoSmithKline, Johnson & Johnson, BeiGene, and Astra Zeneca. At these organizations he led development and regulatory registrations of blockbuster drugs into the U.S. and Chinese markets, directing more than 70 IND approvals and more than 30 NDAs. His medical degree is...2022-06-2935 min
Behind BiotechSeason 2| China: Bing Yuan on Global Outlicensing of Chinese BiotechDr. Bing Yuan is an entrepreneur and a seasoned business executive in business development and licensing (BD&L), marketing and new product strategy. He has made significant contributions to 13 approved global oncology drugs at various stages of product life cycle, including blockbusters such as Keytruda and Glivec. Before founding OnCusp, he was Chief Strategy and Business Officer at CStone Pharmaceuticals. As a senior executive from the beginning, he helped to build the company from scratch to successful IPO and a fully integrated biopharma. At CStone, he established and managed over 10 departments, such as BD&L, public relations, R&D...2022-06-0231 min
Behind BiotechSeason 2| China: Shawn Xiang on Building China's Rare Disease EcosystemShawn Xiang Biography
Dr. Xiang is the CEO of Rarestone Group, a company building the first rare disease ecosystem in China. Dr. Xiang has more than 15 years of leadership experience in pharmaceutical and medical device industries. Prior to RareStone, Shawn was the General Manager of Greater China and Emerging Asia Region at Abbott Diabetes Care, where he led his team and successfully launched FreeStyle Libre in China, Korea and Southeast Asia markets and achieved hyper-growth consecutively over the years. Shawn also led his team to build an ecosystem for patients living with Type 1 Diabetes, through strong collaboration...2022-05-0928 min
Behind BiotechSeason 2| China: Brad Loncar on Investment Risk and Innovation Drivers in Chinese BiotechBrad Loncar Biography
Brad Loncar is a biotechnology industry investor and CEO of Loncar Investments. He is the creator of two Nasdaq-listed biotech focused exchange-traded funds. Brad previously worked in the financial services industry at Franklin Templeton Investments where he was a member of the Management Training Program, and was appointed to serve in a Senior Advisor role at the U.S. Department of the Treasury. He currently writes biotechnology commentary at www.LoncarBlog.com, Nasdaq.com, and contributes opinion pieces to Endpoints News. He’s also the co-host of Biotech Clubhouse, which recaps the week’s biot...2022-04-1452 min
Behind BiotechSeason 2 Introduction: The Dawn of Chinese BiotechWelcome to Season 2 of Behind Biotech. This season, we’re lucky to have a special guest host with us, Patrick Jiang, an MBA candidate at Harvard Business School, and the Co-Founder and CBO of InGel Therapeutics.
This season, we’re taking a behind the scenes look at the booming China biotech scene. We’re profiling a series of founders, executives and investors who are hoping to build the next “Genentech” in Asia .
In introducing this season, we also want to impart an important message to our listeners: In an increasingly global society where politics are unavoidabl...2022-04-1401 min
Behind BiotechSeason 1|Penn: Ricky Barrett on Immunoengineering for Cancer and Empathy for Scientific CommunicationsDr. Ricky Barrett Biography
Ricky is a post-doctoral fellow at the University of Pennsylvania, where he works in the lab of Dr. Ellen Pure to better understand heterogeneity in the tumor stroma and how different cell types interact to influence tumor immune response with the direct goal of developing new stromal based therapeutics. He did his PhD in Biomedical sciences at the University of Central Florida, where he studied the role of innate immunity in metabolic disease. Ricky is currently managing collaborative projects with pharmaceutical companies in academic/industry partnerships. Moreover, Ricky is a leader in scientific communications. He has...2022-03-2540 min
Behind BiotechSeason 1|Penn: Hyun (Michel) Koo on the Need for Innovation in Oral HealthHyun (Michel) Koo, DDS, MS, PhD obtained his DDS from The Sao Paulo State University, Brazil, and later obtained his MS in Food Engineering and PhD in Oral Biology from The University of Campinas, Brazil as well as the University of Rochester Medical Center. Michel joined the faculty at Penn in 2013, where he has led interdisciplinary research integrating oral, biomedical and engineering sciences, culminating with the launch of the Center for Innovation & Precision Dentistry (CiPD), uniting the dental and engineering schools at Penn. Michel has been recognized as an outstanding leader for his pioneering work on understanding and modulating...2022-01-2530 min
Behind BiotechSeason 1|Penn: Aimee Payne on Engineering Precision DermatologyAimee Payne MD, PhD is a Professor of Dermatology and Director of the Clinical Autoimmunity Center of Excellence at the University of Pennsylvania. She received her MD/PhD from Washington University School of Medicine, followed by dermatology residency and fellowship training at the University of Pennsylvania. Her clinical practice specializes in autoimmune blistering diseases including pemphigus and pemphigoid. Her laboratory research has investigated B cell repertoires in pemphigus in order to develop precision medicine therapies for disease. At Penn, Dr. Payne also serves as Core Director for the Skin Biology and Diseases Resource-based Center, Associate Director of the Medical Sc...2021-12-2430 min
Behind BiotechSeason 1| Penn: Anne Chew on Co-Founding Tmunity and Supporting Female Leaders in STEMAnne Chew, PhD, is the Executive Deputy Director for the University of Pennsylvania (UPenn) Center for Cellular Immunotherapies (CCI) and one of the co-founders of Tmunity. She is responsible for overall strategic and operational leadership of all CCI-sponsored research programs and translational development initiatives in cell and gene therapy. Since 2006, she has served in senior regulatory, clinical operations, manufacturing operations and translational sciences roles at UPenn. Dr. Chew has more than 15 years of translational research and development experience in both industry and academic settings. Together with Novartis, Dr. Chew played a pivotal role in preparing the UPenn CTL019 submission...2021-11-1031 min
Behind BiotechSeason 1|Penn: Saar Gill on Creating Next-Gen CAR-T for PatientsSaar is an Associate Professor of Medicine at the Hospital of the University of Pennsylvania, where he practices hematology oncology and leads a research lab. The goals of the Gill lab are to produce effective and safe CAR-T cells for the treatment of hematologic malignancies. Saar and his lab team have co-founded two biotech companies: Carisma Therapeutics, a CAR-Macrophage company, as well as Interius BioTherapeutics, a company developing in vivo CAR-T cell therapy.2021-10-2029 min
Behind BiotechSeason 1|Penn: Jeff Marrazzo on Pioneering Gene TherapyJeff Marrazzo co-founded Spark Therapeutics in 2013 and has led the growth of the company from a research center within the Children’s Hospital of Philadelphia to a fully integrated, commercial gene therapy company.
Under Jeff’s leadership, Spark received regulatory approval for the first gene therapy for a genetic disease in both the U.S. and EU, launched the first gene therapy for a genetic disease in the U.S., and established human proof-of-concept of Spark’s gene therapy platform in both the retina and liver. In more than eight years, Jeff has built an organization of more t...2021-10-0541 minBehind BiotechWelcome to the Behind Biotech PodcastBehind Biotech2021-09-2900 min